[1. J. Hirsh, Heparin, N. Engl. J. Med. 324 (1991) 1565-1574; DOI: 10.1056/NEJM199111283252213.10.1056/NEJM1991112832522131944445]Search in Google Scholar
[2. J. Hirsh, T. E. Warkentin, S. G. Ghaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. Magnus Ohman and J. E. Dalen, Heparin and low-molecular-weight heparin mechanisms of action, Pharmacokinetics, dosing, monitoring, efficacy, and safety, Chest 119 (2001) 64S-94S; DOI: 10.1378/chest.119.1_suppl.64S.10.1378/chest.119.1_suppl.64S11157643]Search in Google Scholar
[3. A. B. Blann, M. J. Landray and G. Y. H. Lip, ABC of antithrombotic therapy: An overview of antithrombotic therapy, B.M.J 325 (2002) 762-765; DOI: 10.1136/bmj.325.7367.762.10.1136/bmj.325.7367.762112427612364307]Search in Google Scholar
[4. J. Hirsh, A. K. Bauer, M. B. Donati, M. Gould, M. M. Samama and J. I. Weitz, Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.), Chest 133 (2008) 141S-159S; DOI: 10.1378/chest.08-0689.10.1378/chest.08-068918574264]Search in Google Scholar
[5. J. Hirsh, T. E. Warkentin, R. Raschke, C. Granger, E. Magnus Ohman and J. E. Dalen, Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety, Chest 114 (1998) 489S-510S; DOI: 10.1378/chest.114.5_ Supplement.489S.]Search in Google Scholar
[6. A. Ziegler and J. Zaia, Size-exclusion chromatography of heparin oligosaccharides at high and low pressure, J. Chromatogr. B 837 (2006) 76-86; DOI: 10.1016/j.jchromb.2006.04.013.10.1016/j.jchromb.2006.04.01316704936]Search in Google Scholar
[7. S. Beni, J. F. K. Limtiaco and C. K. Larive, Analysis and characterization of heparin impurities, Anal. Bioanal. Chem. 399 (2011) 527-539; DOI: 10.1007/s00216-010-4121-x.10.1007/s00216-010-4121-x301516920814668]Search in Google Scholar
[8. D. S. Weitz and J. I. Weitz, Update on heparin: what do we need to know?, J. Thromb. Thrombolysis 29 (2010) 199-207; DOI: 10.1007/s11239-009-0411-6.10.1007/s11239-009-0411-619882363]Search in Google Scholar
[9. A. K. Korir and C. K. Larive, Advances in the separation, sensitive detection, and characterization of heparin and heparan sulfate, Anal. Bioanal. Chem. 393 (2009) 155-169; DOI: 10.1007/s00216-008-2412-2.10.1007/s00216-008-2412-218841350]Search in Google Scholar
[10. W. Mao, C. Thanawiroon and R. J. Linhardt, Capillary electrophoresis for the analysis of glycosaminoglycans and glycosaminoglycan-derived oligosaccharides, Biomed. Chromatogr. 16 (2002) 77-94; DOI: 10.1002/bmc.153.10.1002/bmc.15311857641]Search in Google Scholar
[11. J. Beirne, H. Truchan and L. Rao, Development and qualifi cation of a size exclusion chromatography coupled with multiangle light sca_ ering method for molecular weight determination of unfractionated heparin, Anal. Bioanal. Chem. 399 (2011) 717-725; DOI: 10.1007/s00216-010-4187-5.10.1007/s00216-010-4187-520838778]Search in Google Scholar
[12. F. Zhang, B. Yang, M. Ly, K. Solakyildirim, Z. Xiao, Z. Wang, J. M. Beaudet, A. Y. Torelli, J. S. Dordick and R. J. Linhardt, Structural characterization of heparins from diff erent commercial sources, Anal. Bioanal. Chem. 401 (2011) 2793-2803; DOI: 10.1007/s00216-011-5367-7. 13. J. E. Knobloch and P. N. Shaklee, Absolute molecular weight distribution of low-molecular-weight heparins by size-exclusion chromatography with multiangle laser light sca_ ering detection, Anal. Biochem. 245 (1997) 231-241; DOI: 10.1006/abio.1996.9984.10.1006/abio.1996.9984]Search in Google Scholar
[14. X. Guo, M. Condra, K. Kimura, G. Berth, H. Dautzenberg and P. L. Dubin, Determination of molecular weight of heparin by size exclusion chromatography with universal calibration, Anal. Biochem. 312 (2003) 33-39; DOI: 10.1016/S0003-2697(02)00428-1.10.1016/S0003-2697(02)00428-1]Search in Google Scholar
[15. S. Bertini, A. Bisio, G. Torri, D. Bensi and M. Terbojevich, Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array, Biomacromolecules 6 (2005) 168-173; DOI: 10.1021/bm049693s.10.1021/bm049693s]Search in Google Scholar
[16. O. F. Swoap and M. H. Kuizenga, The sheep plasma method for the bioassay of heparin preparations, J. Am. Pharm. Assoc. 38 (1949) 563-565; DOI: 10.1002/jps.3030381012.10.1002/jps.3030381012]Search in Google Scholar
[17. C. D. Sommers, N. Montpas, A. Adam and D. A. Keire, Characterization of currently marketed heparin products: adverse event relevant bioassays, J. Pharm. Biomed. Anal. 67-68 (2012) 28-35; DOI: 10.1016/j.jpba.2012.04.017.10.1016/j.jpba.2012.04.017]Search in Google Scholar
[18. European Pharmacopoeia, 8th ed., Vol. 2, Council of Europe, Strasbourg 2013, pp. 2390-2391.]Search in Google Scholar
[19. United States Pharmacopoeia 36, National Formulary 31, Vol. 2, USP Convention, Rockville 2013, pp. 3801-3805.]Search in Google Scholar
[20. P. K. Smith, A. K. Mallia and G. T. Hermanson, Colorimetric method for the assay of heparin content in immobilized heparin preparations, Anal. Biochem. 109 (1980) 466-473; DOI: 10.1016/0003-2697(80)90679-X.10.1016/0003-2697(80)90679-X]Search in Google Scholar
[21. I. Nemcova, P. Rychlovsky, M. Havelcova and M. Brabcova, Determination of heparin using flow injection analysis with spectrophotometric detection, Anal. Chim. Acta 401 (1999) 223-228; DOI: 10.1016/S0003-2670(99)00472-9.10.1016/S0003-2670(99)00472-9]Search in Google Scholar
[22. A. Karewicz, K. Zasada, K. Szczubialka, S. Zapotoczny, R. Lach and M. Nowakowska, “Smart” alginate-hydroxypropylcellulose microbeads for controlled release of heparin, Int. J. Pharm. 385 (2010) 163-169; DOI: 10.1016/j.ij pharm.2009.10.021.]Search in Google Scholar
[23. C. E. Doneanu and W. Chen, Impurity evaluation of heparin sodium by anion exchange chromatography, Waters Application Note, Milford (MA) 2009.]Search in Google Scholar
[24. X. Xu, Y. Li, A. Cui and H. Chen, High Resolution Analysis of Heparin and Heparin-like Impurities on GlycomixTM - an Anion Exchange Column. Glycan separation, Sepax Application Note, Sepax Technologies, Delaware 2012.]Search in Google Scholar
[25. M. L. Trehy, J. C. Reepmeyer, R. E. Kolinski, B. J. Westenberger and L. F. Buhse, Analysis of heparin sodium by SAX/HPLC for contaminants and impurities, J. Pharm. Biomed. Anal. 49 (2009) 670-673; DOI: 10.1016/j.jpba.2008.12.013.10.1016/j.jpba.2008.12.01319167854]Search in Google Scholar
[26. D. A. Keire, M. L. Trehy, J. C. Reepmeyer, R. E. Kolinski, W. Ye, J. Dunn, B. J. Westenberger and L. F. Buhse, Analysis of crude heparin by 1H NMR, capillary electrophoresis, and strong-anion-exchange- HPLC for contamination by over sulfated chondroitin sulfate, J. Pharm. Biomed. Anal. 51 (2010) 921-926; DOI: 10.1016/j.jpba.2009.10.017.10.1016/j.jpba.2009.10.01719959313]Search in Google Scholar
[27. D. A. Keire, D. J. Mans, H. Ye, R. E. Kolinski and L. F. Buhse, Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches, J. Pharm. Biomed. Anal. 52 (2010) 656-664; DOI: 10.1016/j.jpba.2010.02.019.10.1016/j.jpba.2010.02.01920233649]Search in Google Scholar
[28. M. Radivojša, I. Grabnar and P. Ahlin Grabnar, Thermoreversible in situ gelling poloxamer-based systems with chitosan nanocomplexes for prolonged subcutaneous delivery of heparin: Design and in vitro evaluation, Eur. J. Pharm. Sci. 50 (2013) 93-101; DOI: 10.1016/j.ejps.2013.03.002.10.1016/j.ejps.2013.03.00223524253]Search in Google Scholar
[29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneva, November 2005.]Search in Google Scholar
[30. Q. Jiao and Q. Liu, Mechanism of interference and Azur A response in the heparin assay, Anal. Le . 31 (1998) 1311-1323; DOI: 10.1080/00032719808002868. 10.1080/00032719808002868]Search in Google Scholar